Skip to main content

Advertisement

SpringerLink
Log in

Statin but not Non-Statin Lipid-Lowering Drugs Decrease Fracture Risk: A Nation-Wide Case-Control Study

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Introduction

Discrepant results have been reported on association between treatment with lipid lowering drugs and fracture risk. Several studies have failed to demonstrate an effect of statins on bone mineral density. Therefore, the epidemiological findings of a reduced fracture risk may be due to selections bias, e.g. a healthy drug user effect. If so, the reduced fracture risk is most likely independent of type of lipid lowering drug.

Aim

We assessed fracture risk in users of various lipid-lowering drugs.

Methods

In a case-control design, we compared 124,655 fracture cases with 373,962 age- and gender-matched controls. We used computerized registers to assess individual drug use and related these data to individual fracture data and information on potential confounders.

Results

Use of statins was associated with a reduced risk of any fracture (adj. OR 0.87; 95% CI, 0.83–0.92) and hip fractures (adj. OR 0.57; 95% CI, 0.48–0.69). Risk of hip fracture decreased with increased accumulated dose of statins. This was true in men and in women and in subjects younger and older than 65 years of age. However, fracture risk was not reduced in patients treated with pravastatin (adj. OR 1.02; 95% CI, 0.89–1.17) or non-statin lipid lowering drugs (adj. OR 0.99; 95% CI, 0.86–1.15).

Conclusions

The reduced fracture risk in users of lipid lowering drugs is apparently specifically related to users of non-pravastatin statins. Our findings do not support the hypothesis of a healthy drug user effect as an explanation for the reduced fracture risk in users of statins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of Bone Formation in Vitro and in Rodents by Statins. Science 286:1946–1949

    Article  PubMed  CAS  Google Scholar 

  2. Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609–618

    Article  PubMed  CAS  Google Scholar 

  3. Oxlund H, Dalstra M, Andreassen TT (2001) Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299–304

    Article  PubMed  CAS  Google Scholar 

  4. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142

    Article  PubMed  CAS  Google Scholar 

  5. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of Simvastatin on Bone Turnover and BMD: A 1−Year Randomized Controlled Trial in Postmenopausal Osteopenic Women. J Bone Miner Res 19:737–744

    Article  PubMed  CAS  Google Scholar 

  6. Schoofs MW, Sturkenboom MC, van der KM, Hofman A, Pols HA, Stricker BH (2004) HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 19:1525–1530

    Article  PubMed  CAS  Google Scholar 

  7. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA Reductase Inhibitors and the Risk of Fractures. JAMA 283:3205–3210

    Article  PubMed  CAS  Google Scholar 

  8. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients. JAMA 283:3211–3216

    Article  PubMed  CAS  Google Scholar 

  9. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydromethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188

    Article  PubMed  CAS  Google Scholar 

  10. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L (2004) Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos Int 15:452–458

    PubMed  Google Scholar 

  11. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HAP (2004) Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials. Arch Intern Med 164:146–152

    Article  PubMed  CAS  Google Scholar 

  12. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537–540

    Article  PubMed  CAS  Google Scholar 

  13. Ray WA, Daugherty JR, Griffin MR (2002) Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276–279

    Article  PubMed  CAS  Google Scholar 

  14. Pedersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921–1922

    Article  PubMed  CAS  Google Scholar 

  15. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855

    Article  PubMed  Google Scholar 

  16. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509–512

    Article  PubMed  CAS  Google Scholar 

  17. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD (2003) Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women’s Health Initiative Observational Study. Ann Intern Med 139:97–104

    PubMed  CAS  Google Scholar 

  18. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526

    PubMed  CAS  Google Scholar 

  19. Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398–2399

    Article  PubMed  CAS  Google Scholar 

  20. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268

    PubMed  CAS  Google Scholar 

  21. Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac Disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156:1–10

    Article  PubMed  Google Scholar 

  22. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028

    PubMed  CAS  Google Scholar 

  23. Nielsen GL, Sorensen HT, Zhou W, Steffensen FH, Olsen J (1997) The pharmacoepidemiologic prescription database of North Jutland - a valid tool in pharmacoepidemiological research. Int J Risk Safety Med 10:203–205

    Google Scholar 

  24. Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug Utilization Studies: Methods and Uses. WHO Regional Publications, Copenhagen, pp 55–58

    Google Scholar 

  25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Article  PubMed  CAS  Google Scholar 

  26. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 56:221–229

    Article  PubMed  Google Scholar 

  27. Miettinen OS (1985) Theoretical epidemiology: Principles of occurrence research in medicine. Wiley & Sons, New York

    Google Scholar 

  28. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218–2219

    Article  PubMed  CAS  Google Scholar 

  29. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581–589

    Article  PubMed  CAS  Google Scholar 

  30. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1−year treatment with fluvastatin or pravastatin on bone. The American Journal of Medicine 110:584–587

    Article  PubMed  CAS  Google Scholar 

  31. Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766–770

    Article  PubMed  CAS  Google Scholar 

  32. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380–384

    Article  PubMed  CAS  Google Scholar 

  33. Johansen A, Evans RJ, Stone MD, Richmond PW, Lo SV, Woodhouse KW (1997) Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury 28:655–660

    Article  PubMed  CAS  Google Scholar 

  34. Sahlin Y (1990) Occurrence of fractures in a defined population: a 1-year study. Injury 21:158–160

    Article  PubMed  CAS  Google Scholar 

  35. Sanders KM, Pasco JA, Ugoni AM, Nicholson GC, Seeman E, Martin TJ, Skoric B, Panahi S, Kotowicz MA (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res 13:1337–1342

    Article  PubMed  CAS  Google Scholar 

  36. Francis RM, Baillie SP, Chuck AJ, Crook PR, Dunn N, Fordham JN, Kelly C, Rodgers A (2004) Acute and long-term management of patients with vertebral fractures. QJM 97:63–74

    Article  PubMed  CAS  Google Scholar 

  37. Hoidrup S, Gronbaek M, Gottschau A, Lauritzen JB, Schroll M (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 149:993–1001

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The Danish Medical Research Council provided financial support. The National Bureau of Statistics, Denmark is acknowledged for its help in providing data.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus Sygehus, Tage Hansens Gade 2, Aarhus C, DK-8000, Denmark

    L. Rejnmark, P. Vestergaard & L. Mosekilde

Authors
  1. L. Rejnmark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Vestergaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Mosekilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Rejnmark.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rejnmark, L., Vestergaard, P. & Mosekilde, L. Statin but not Non-Statin Lipid-Lowering Drugs Decrease Fracture Risk: A Nation-Wide Case-Control Study. Calcif Tissue Int 79, 27–36 (2006). https://doi.org/10.1007/s00223-006-0024-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-006-0024-4

Keywords

Search

Navigation